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Abstract
Background
Moderate correlation exists between the imaging quantification of brain white matter lesions
and cognitive performance in people with multiple sclerosis (MS). This may reflect the
greater importance of other features, including subvisible pathology, or methodological limi-
tations of the primary literature.
Objectives
To summarise the cognitive clinico-radiological paradox and explore the potential methodo-
logical factors that could influence the assessment of this relationship.
Methods
Systematic review and meta-analysis of primary research relating cognitive function to white
matter lesion burden.
Results
Fifty papers met eligibility criteria for review, and meta-analysis of overall results was possi-
ble in thirty-two (2050 participants). Aggregate correlation between cognition and T2 lesion
burden was r = -0.30 (95% confidence interval: -0.34, -0.26). Wide methodological variability
was seen, particularly related to key factors in the cognitive data capture and image analysis
techniques.
Conclusions
Resolving the persistent clinico-radiological paradox will likely require simultaneous evalua-
tion of multiple components of the complex pathology using optimum measurement tech-
niques for both cognitive and MRI feature quantification. We recommend a consensus
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Introduction
Cognitive impairment is seen in 43–70% of people with multiple sclerosis (MS), exhibiting a
variable pattern of deficits between individuals [1]. The most frequently detected deficits
include a reduction in information processing speed, executive functions, attention, and long-
term memory. Impairment of information processing may represent the core cognitive deficit
[2], consistent with the model of a disconnection syndrome [3]. The underlying pathology is
complex, including both focal and diffuse abnormalities of the central nervous system that
affect both white and grey matter structures [4]. Components of this pathology have been
increasingly amenable to in vivo quantification through magnetic resonance imaging (MRI)
and associated image analysis techniques [5]. The impact of pathology on phenotype is also
influenced by lifetime intellectual enrichment (‘cognitive reserve’) [6], lifestyle variability (cog-
nitive leisure), as well as comorbidities, ageing, and medications.
Although aspects of the ‘global’ pathological burden affecting the brains of people with MS
can be readily estimated by abnormalities such as T2 hyperintense lesions that are visible on
structural MRI, limited correlation exists between these measures and the clinical phenotype.
This has been termed the ‘clinico-radiological paradox’ (CRP) and is well described for both
physical and cognitive impairments [7]. The CRP presents a fundamental challenge with
respect to mechanistic understanding of the relationship between pathology and phenotype in
MS, and to the use of MRI metrics in clinical decision-making at the individual-subject level.
Several explanations have therefore been proposed in order to resolve the CRP, including rec-
ognition that summation of whole-brain metrics fails to account for variability between sub-
jects in the spatial patterning of multifocal pathology [8]. Although such consideration has a
clear corollary through the fundamental principles of localisation in clinical neurology, it pro-
vides a less satisfactory explanation with respect to cognitive impairments, particularly for cog-
nitive functions such as information processing speed where the functional neuroanatomy
involves widespread connectivity between brain regions [9, 10].
Additional potential contributors to the ‘cognitive CRP’ include fundamental issues with
the evaluation of cognition such as whether any existing test can isolate and quantify a neuroa-
natomically distributed cognitive function. Or, whether multidimensional cognitive assess-
ment through ‘cognitive batteries’ provides a valid quantitative assessment of ‘global’ cognitive
performance. Such ‘global’ evaluation may be contingent on pre-requisite and relatively local-
ised functions such as sustained attention that are subject to the potential confound of variable
spatial patterning. Although mitigated by the use of batteries with normative data simulta-
neously developed for component tests, judgement with respect to the latter remains a funda-
mental principle applied in clinical neuropsychology [11]. Separately, critical issues also arise
in the quantification of total pathological burden by structural brain MR imaging. These
include the known insensitivity of existing metrics for potentially critical aspects of disease
pathology such as grey matter lesions [12] and a failure to adequately quantify neuroaxonal
loss or underlying subvisible/diffuse pathology. Critically, these aspects of the complex
pathology may be independent at the individual-subject level [13], rendering assessment of T2
hyperintense lesion burden as an inadequate account of the total (multifaceted) pathological
burden.
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In addition, modest correlation of total MRI-visible white matter lesion burden to
cognitive status may reflect attenuation due to psychometric limitations in the methodologies
for quantification of both cognitive and MRI features [14], as well as aspects of study design
including participant selection. We therefore performed a systematic review and meta-analysis
of the published literature describing the relationship between cognitive function and the
total burden of white matter pathology detected by standard structural brain MRI. Our
aim was first to confirm the modest correlations that have been previously described [15], and
second to explore the potential methodological issues that may affect the observed
relationship.
Methods
Design of the systematic review, meta-analysis, and manuscript was based on PRISMA (‘Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analyses’) guidelines [16].
Protocol, information sources and search strategy
The study protocol was documented in advance. Medline, Embase, and Web of Science data-
bases were searched for English language papers on 1st July 2015, with no date restrictions
(S1 Appendix). Review articles were excluded, but relevant reviews published in the last 10
years were screened for references. Archives of the journals Neurology, Multiple Sclerosis and
the American Journal of Neuroradiology were also hand-searched for relevant articles pub-
lished in the previous ten years. Search terms were: ‘magnetic resonance imaging’, ‘multiple
sclerosis’, ‘cognitive’, ‘cognition’, related terms and abbreviations of these.
Study selection and eligibility criteria
Initial screening of abstracts was performed by a single author (DM). Full articles were then
retrieved and eligibility assessment performed in a standardized manner, with a final decision
over study inclusion taken in consensus with a second reviewer (PC). Eligibility criteria were:
English language and peer-reviewed publications reporting data from adults with clinically
definite MS as primary research with a primary aim of relating cognition to T1w, T2w, FLAIR
or PD metrics of total brain white matter lesion burden. Imaging outcomes for total lesion vol-
ume or area, and lesion counts or scores, were all accepted as valid measures of whole brain
lesion burden. Similarly, any measure of cognitive function with face-validity was accepted.
Studies were excluded if reporting exploratory or secondary analysis, or if lesion burden
was only related to longitudinal change in cognitive function. Where studies examined both
cross-sectional and longitudinal outcomes, the baseline cross-sectional analyses were used.
When overlap of reported cohorts was identified and clarification from the original investiga-
tors was not possible, a conservative approach was adopted with inclusion of only the earliest
dated relevant article. Studies within the systematic review were suitable for meta-analysis if
they reported an overall effect for the relationship of imaging metrics to a single measure of
cognition defined by either a single cognitive test, or a summary result from a cognitive
battery.
Data collection
Data was extracted by a single author (DM) using a standardized form that captured (1) char-
acteristics of the participants, including age, sex and disease phenotype; (2) cognitive testing
methods including blinding and identity of the tester; (3) image acquisition methods; (4)
image analysis methods including training and blinding of investigators, software tools used,
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whether measures of intra- and inter-rater reliability were provided; and (5) statistical analysis
methods including controlling for potential confounding factors. A study quality assessment
tool (S2 Appendix) was also developed based on STROBE (‘Strengthening the Reporting of
Observational studies in Epidemiology’) guidelines [17] to evaluate the risk of bias in individ-
ual studies. The authors for one paper were contacted for further information and numerical
data was provided.
Summary measures and synthesis of results
Summary measures were recorded if relating MRI metrics to an overall measure of cognitive
function or to a single cognitive test. Where summary measures were provided both unad-
justed and adjusted for potentially confounding clinical covariates, adjusted results were used.
Correlation coefficients or the difference in lesion burden between groups defined by cognitive
status were accepted as summary measures, with preference given to correlations if both were
available [18]. All reported summary measures were converted into effect sizes and inverted as
necessary so that negative values always indicated an association of lower cognitive scores to
higher lesion burdens. Standardized mean differences were calculated from studies reporting
group comparisons, prior to conversion to equivalent correlations (r). An approximation to
the standard deviation was estimated as necessary based on available measures of dispersion
(e.g. interquartile range or range). In studies with two impaired groups defined by specific cog-
nitive deficits, these groups were combined before calculation of a standardized difference
from a non-impaired group. The Fisher’s z transformation was used prior to calculation of an
aggregate summary effect, with conversion back to r for reporting of overall meta-analysis
findings and confidence intervals.
An aggregate summary effect was calculated using maximum likelihood estimation [19],
taking into account the size of the various studies; this method allows incorporation of those
studies reporting non-significant results without providing their estimate. Separate analyses
were carried out for studies measuring hyperintense lesion burden on T2w, FLAIR and/or PD
sequences, and for the subgroup of studies evaluating T1w hypointense lesion volume. Hetero-
geneity was assessed by Cochran’s Q and the I2 statistic [20], based on the studies providing
specific estimates of the effect size. All analyses were performed using the statistical software R,
version 3.2.4.
Risk of bias across studies
Our eligibility criteria required a stated primary aim to evaluate the relationship between cog-
nitive status and brain imaging metrics so that we might minimize the influence of reporting
bias from post hoc analyses. Within the included studies, we recorded analyses that were
described without results being provided. A funnel plot was also evaluated visually and tested
formally using Egger’s regression test for asymmetry.
Additional analyses
An alternative aggregate effect size was calculated using quality scores as an additional scaling
factor. A sensitivity analysis examining the effect of using an alternative random-effects model,
with DerSimonian and Laird methodology, was carried out for all studies providing data com-
patible with precise estimates of the effect size. Subgroup analyses of studies using the Paced
Auditory Serial Addition Test (PASAT) and Symbol Digit Modalities Test (SDMT) were also
pre-specified to investigate whether focusing on distributed cognitive function would improve
correlations with overall lesion burden and replicate previous findings [15].
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Results
Study selection
A total of 3882 studies were identified by the initial literature search, 1975 of which were dupli-
cates (Fig 1). Year-on-year increases were seen in the publication rate identified through the
initial search (S1 Fig). No additional studies were included following hand searching of journal
archives. After review of abstracts, 139 manuscripts were retrieved. Ninety were subsequently
excluded, most frequently (35/90 = 39%) because the study aim was not relevant. A total of
fifty papers met all inclusion criteria [21–70] spanning the period 1987–2015.
Thirty studies provided usable summary measures relating hyperintense T2w/FLAIR/PD
lesion burden to cognitive function. Two studies reported a ‘non-significant’ result and one
study was excluded from meta-analysis as the reported summary measure was internally
inconsistent with other reported results and significance levels. The remaining seventeen stud-
ies did not provide results suitable for use in meta-analysis, reporting only individual results
for each cognitive subtest (n = 12) or multiple regression modeling with simultaneous assess-
ment of several brain imaging metrics (n = 5). Thirteen studies related cognition to T1
Fig 1. Flowchart showing articles retrieved and considered at each stage of the review process.
https://doi.org/10.1371/journal.pone.0177727.g001
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hypointense lesion burden, of which eleven provided usable summary measures and two
reported ‘non-significant’ results.
Participant characteristics
The total number of subjects from all included studies was 2891. Individual study size ranged
from 17 to 327 participants (mean 58, median 45; Fig 2a). Forty-four studies specified the sex
ratio, all but one having a female majority. The range of mean participant age (provided in
47/50 studies) was 31–55 years. No study used age of disease onset in its eligibility criteria.
Twenty-six studies included participants with a mixture of disease courses; thirteen studies
recruited exclusively relapsing-remitting disease, six studies progressive disease, two ‘benign’,
and three did not specify the participants’ disease course.
MR brain imaging acquisition
The majority (29/50 studies) used 1.5T scanners. Ten studies used scanners with below 1.5T
magnets for some or all participants’ imaging, seven used 3T scanners, one used both 1.5 and
3T scanners and three did not specify the scanner field strength. Details of the imaging proto-
col were given in all but seven studies.
Fig 2. Showing factors relevant to study quality including histograms of a) numbers of participants with MS in
individual studies and b) overall quality scores, and c) the reporting of individual factors contributing to the
overall quality score.
https://doi.org/10.1371/journal.pone.0177727.g002
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Image analysis
The sequence(s) used to measure lesion volume was specified in forty-three studies. Twenty-
six specified the number of people involved in the lesion analysis, a single observer in fourteen.
The anatomical boundaries of evaluation were explicitly defined in two studies and a sample
image was provided by five studies. A wide variety of approaches were used for the quantifica-
tion of lesion burden. These included lesion counts (two studies) or weighted lesion scores (six
studies), manual lesion outlining either on hard copies (two studies) or within viewing soft-
ware (six studies), and the use of semi-automated methods (thirty-one studies). Of the six
studies using lesion scores, five different scoring systems were used. One study used both man-
ual and semi-automated measurements (for different sequences), one used manual lesion out-
lining and an absolute lesion count, and in one study the methodology was unclear. In the
thirty-two studies using semi-automated measurement tools, the software used was specified
or references provided in 25 studies (78%), covering fourteen different software packages. In
eighteen of these studies the named software was publically available (eleven different soft-
wares). The remaining studies did not specify their software. A manual editing stage for soft-
ware-generated lesion masks was specified in five studies (16%) and the person performing
this was described in two studies. In the ten studies using fully manual lesion outlining, the
person performing this was described in six. Only two studies provided an indication of inter-
observer agreement and one study intra-observer reproducibility. Seven studies mentioned
previous measures of reproducibility or results on training data sets. Only five percent of stud-
ies calculating a lesion volume or area (2/42) normalized to intracranial volume.
Cognitive testing
The cognitive assessor and their training was unclear in thirty-eight studies. Of defined batter-
ies, the most commonly used was Rao’s Brief Repeatable Battery (12/50), followed by the Mini-
mal Assessment of Cognitive Function in MS (5/50), used with modifications or additional
tests in eight (67%) and two (40%) studies respectively. Unique collections of tests were found
in twenty-seven studies. The SDMT or PASAT were used either exclusively or as part of a
wider battery in thirty studies. Substantial variability was seen in how raw cognitive scores
were processed prior to their use in the evaluation of a possible relationship with imaging met-
rics. Methods included use of unadjusted scores, standardization, and the deployment of
group classifiers. Standardization was performed using either historic- (published or unpub-
lished) or contemporary- (matched or unmatched for participant characteristics) control data.
Group classifiers were either based on internal (patient) or external (normative) reference
cohorts. The specific thresholds used to define impairment on individual tests were also vari-
able, including 1, 1.5, and 2 standard deviations from the reference mean, and those based on
centiles. Moreover, the number of failed tests used to define overall cognitive impairment was
also variable (S1 Table). Consideration of the effect of potential confounders also varied
between studies, both in the recording of relevant data and whether it was adjusted for in the
analysis. Some studies adjusted for age (n = 18), sex (n = 12), education level (n = 13) and/or
affective disorders (n = 15). Drug treatments and premorbid IQ were both adjusted for in
three studies. Cognitive leisure activities were neither measured nor adjusted for in any study.
Statistical analysis
Summary measures were provided through univariate correlations (n = 37) and/ or group
comparisons based on cognitive status (n = 24). Four studies divided participants into groups
dependent on radiological features. Fourteen studies constructed statistical models predicting
The cognitive clinico-radiological paradox in multiple sclerosis: A systematic review and meta-analysis
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cognitive performance based on imaging and other laboratory, demographic, or clinical
markers.
Reporting quality and risk of bias within studies
A range of study-specific quality scores was seen (mean 42%, SD 11%; Fig 2b). Among individ-
ual elements of the composite quality score, complete reporting was provided most frequently
for eligibility criteria and outcome measures (Fig 2c). In contrast, no study provided complete
reporting of potential confounding factors, measurement methodology, or study size
rationale.
Results of individual studies
Studies directly reporting correlation coefficients relating cognitive performance to T2 hyper-
intense lesion burden ranged from -0.6 to -0.23. Standardised mean differences ranged from
-2.70 to 0.23, equivalent to correlations of -0.80 to 0.11.
Synthesis of results
The aggregate effect size relating cognitive performance to T2 hyperintense lesion burden was
r = -0.30 (95% confidence interval: -0.34 to -0.26; Fig 3). There was evidence of possible hetero-
geneity (Q = 43.62, df = 29, p = 0.04; I2 = 33.5%). The aggregate effect size relating cognitive
performance to T1 hyperintense lesion burden was r = -0.26 (95% CI: -0.32, -0.20; Q = 20.4,
df = 10, p = 0.025, I2 = 51.0%, see S3 Appendix for further details).
Risk of bias across studies
Funnel plot inspection (S2 Fig) and Egger’s test of asymmetry gave an equivocal result
(p = 0.05). We therefore explored possible underlying sources of heterogeneity [71]. Reporting
biases could not be evaluated as study protocols were not published prospectively. Despite
methodological heterogeneity apparent from our quality scoring, no correlation was seen
between overall quality score and effect size (r = -0.18, p = 0.34). Exploratory meta-analysis
using quality scores as an additional weighting factor returned an effect size similar to that of
our primary analysis (r = -0.30; 95% CI: -0.36, -0.24). In order to explore the possibility of ‘true
heterogeneity’ between study effect sizes, we performed a sensitivity meta-analysis using a ran-
dom effects model, giving an overall effect size similar to that of our primary analysis (r =
-0.33; 95% CI: -0.38, -0.27). Further sensitivity analyses, comparing scanner field strength and
type of lesion quantification method did not demonstrate a measurable subgroup difference in
heterogeneity from the small number of studies using high (3T) or low (below 1T) field scan-
ners, or from those using lesion counts or scores.
Additional analyses
Alternative cognitive endpoints. Exploratory meta-analyses were performed on two
widely used measures of information processing speed (IPS), the SDMT and PASAT (S4 & S5
Appendices). Our a priori hypothesis was that total lesion burden would have a stronger corre-
lation with these tests of distributed cognition function (IPS) compared to the mixture of dis-
tributed and localized functions in our primary analysis. The summary effect size for SDMT
was r = - 0.37 (95% CI: -0.43, -0.31; n = 13 studies) and for PASAT was r = - 0.28 (95% CI:
-0.34, -0.22; n = 15 studies).
The cognitive clinico-radiological paradox in multiple sclerosis: A systematic review and meta-analysis
PLOS ONE | https://doi.org/10.1371/journal.pone.0177727 May 15, 2017 8 / 16
Discussion
Our results confirm a modest correlation (r = - 0.30) between MRI measures of total brain
white matter lesions and cognitive function in people with MS. Although some variability was
observed between studies in the magnitude of the reported relationship, no large (>100 partic-
ipants) single study demonstrated a strong correlation. We therefore sought to explore
whether technical and methodological factors may have been important in attenuating the
reported correlation.
Fig 3. Forest plot of the individual studies showing their effect sizes as correlation coefficients. Box sizes are inversely proportional
to study variance. Manuscripts reporting “non-significant” results without a point estimate are represented by circles. Aggregate effect size:
r = -0.30; 95% confidence interval: -0.34, -0.26.
https://doi.org/10.1371/journal.pone.0177727.g003
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Substantial variability was seen with respect to study design, including the approaches used
to quantify both cognitive function (see review by Fischer et al [72]) and lesion burden, and
the adjustment for other variables that influence cognition (e.g. education, premorbid IQ and
drugs). For cognitive assessment, this may represent a largely historic issue as a global move-
ment is now established to harmonise evaluation and scoring through the Brief International
Cognitive Assessment for MS (BICAMS) initiative [73]. In contrast, the optimum method to
generate quantifiable measures of lesion burden from brain imaging data lacks emergent con-
sensus. Recent initiatives to harmonise MR acquisition protocols are welcome [74, 75], how-
ever no similar initiative exists for image analysis techniques. Semi-automated approaches
were the most frequently used (62%) and therefore merit particular consideration. While effec-
tive manual editing is clearly dependent on adequate training of the operator, the automated
(software) component is more challenging to benchmark. We recommend that authors should
routinely report the software used. Separately, the field risks delaying progress and reducing
the potential for collaboration due to the many differing software packages used. Of the
twenty-four studies naming software, ten different publicly available (commercial or open
source) packages were used, and a further three packages that were developed ‘in house’. To
our knowledge, no comparative study has been performed on a common dataset to evaluate
agreement between these varied approaches. It is therefore our view that a new consensus ini-
tiative is required to support an image analysis framework in MS that enables benchmarking
while also supporting ongoing innovation.
Despite our finding of substantial methodological variability between studies, formal testing
for heterogeneity in our primary meta-analysis returned an equivocal result. This indicates
that methodological variability between studies cannot provide a sufficient explanation for the
cognitive-CRP. However, measurement errors within all published studies may have attenu-
ated observed correlations in the face of a higher ‘true’ correlation [14]. Greater recognition
and transparency around measurement error for both cognitive and lesion-burden quantifica-
tion would therefore be beneficial to the field.
As previously noted, resolving the cognitive-CRP may require consideration of the spatial
patterning of lesions with simultaneous evaluation of other aspects of MS pathology that may
be both phenotypically relevant and independent from the burden of white matter hyperinten-
sities [76, 77]. However, a further potential contributor is the pathological variability of white
matter T2 hyperintense lesions. Conventional MRI is unable to distinguish the extent of intra-
lesional inflammatory infiltrate, demyelination, remyelination, axonal damage, or gliosis [78].
If cognitive impairment reflects only some of these pathological features, then the remainder
will contribute only measurement error; improved MR-based quantification of individual
lesion characteristics may therefore be critical.
Our findings may have been limited by an overly inclusive approach to both the evaluation
of cognition and white matter lesion burden. With respect to the former, we saw a higher
aggregate correlation between white matter lesion burden and cognition measured by the
SDMT–a measure of information processing speed, understood to reflect widely distributed
brain connectivity–than was seen for cognition as defined in the primary analysis. Notably, rel-
atively few studies in our review used >1.5T field-strength scanners, in part reflecting the
recent shift away from exploring the relationship between phenotype and T2 hyperintense
lesion burden, focusing instead on the possible relevance of other MR metrics. We therefore
interpret our sensitivity analysis for the effect of magnet field strength to lack sufficient data
for a definitive conclusion. We would encourage re-evaluation of this relationship as the litera-
ture evolves with respect to 3T acquisition and/or in cohorts scanned on both low and high
magnetic field scanners. Finally, a substantial body of potentially relevant data was excluded
from our review as the primary aim of the study was unclear or reported findings were
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secondary/exploratory analyses. Finally, despite our best efforts to apply a systematic approach,
all reviews are conducted by researchers who bring unconscious bias [79].
Conclusions
We replicate the finding that modest correlation (r = - 0.30) exists between MRI measures of
total brain white matter lesion burden and cognitive function in people with MS. However,
the quantification techniques for both cognitive and MR features were highly variable, and this
may have attenuated the observed strength of the association. An accurate assessment of the
relationship requires optimum measurement techniques; this is a prerequisite to meaningful
investigation of the clinico-radiological paradox through simultaneous evaluation of multiple
components of the complex pathology. We therefore make the following recommendations:
1. A new consensus initiative is advanced to support an image analysis framework in MS that
enables benchmarking while also supporting ongoing innovation.
2. Greater recognition and transparency are fostered around measurement error for both cog-
nitive and lesion burden quantification.
3. Reporting of observational research adheres to best-practice guidance such as provided by
the STROBE statement.
4. Attempts to resolve the cognitive clinico-radiological paradox should adopt a more multidi-
mensional approach to understanding white matter lesions with simultaneous consider-
ation to multiple elements of the quantifiable pathology, whilst also incorporating potential
clinical confounders of the relationship.
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